BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
BiomX Inc. COmmon Stock (PHGE)
Company Research
Source: GlobeNewswire
Recent acquisition of Adaptive Phage Therapeutics creates leader in phage therapy with advanced, clinical-stage pipeline Closed concurrent $50 million financing to support BX004 and BX211 programs through key data readouts expected in 2025 Patient recruitment on track in BX211 Phase 2 trial in Diabetic Foot Osteomyelitis (“DFO”), with topline results expected in Q1 2025 Company will host a conference call and webcast today at 8:00 am ET CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 03, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update. “2023 marked a year of great progress for BiomX, highlighted by the positive results from our Phase 1b/2a trial which demonstrated that a short course of tr
Show less
Read more
Impact Snapshot
Event Time:
PHGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PHGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PHGE alerts
High impacting BiomX Inc. COmmon Stock news events
Weekly update
A roundup of the hottest topics
PHGE
News
- BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024) [Yahoo! Finance]Yahoo! Finance
- BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)GlobeNewswire
- BiomX Announces the Appointment of Susan Blum to its Board of DirectorsGlobeNewswire
- BiomX Inc. (AMEX:PHGE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- BiomX Announces Compliance with NYSE Guidelines on Audit Opinion DisclosureGlobeNewswire
PHGE
Earnings
- 11/14/23 - Beat
PHGE
Sec Filings
- 4/29/24 - Form S-3
- 4/15/24 - Form 3
- 4/15/24 - Form 8-K
- PHGE's page on the SEC website